Seth Lerner, MD; Ron Bukowski, MD; Chris Logothetis, MD; Richard Williams, MD; Michael Sorodsky, MD
This program deals with testes cancer; bladder cancer- BCG, alternatives to BCG therapy, and metastatic bladder cancer; and renal cell cancer - single agent therapies including IL-2 high dose and alpha interferon, combination therapy of IL-2 low dose and alpha interferon, and surgery to treat renal cell - does it improve survivability.
|